The phosphoinositide 3 kinase (PI3K)/Akt/mammalian (or mechanistic) target of rapamycin (mTOR) pathway is a complicated intracellular pathway, which leads to cell growth and tumor proliferation and plays a significant role in endocrine resistance in breast cancer.Cited by: 231. Oct 02, 2015 · Activation of the phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in breast cancer. There is preclinical data to support inhibition of the pathway, and phase I to III trials involving inhibitors of the pathway have been or are being conducted in solid tumors and breast cancer.Cited by: 86.
Jan 15, 2013 · The phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway is commonly dysregulated in breast cancer. In preclinical studies, hyperactivation of the PI3K pathway has been linked to resistance to both endocrine therapy and trastuzumab (Herceptin).Cited by: 25. In addition to treating pNET, mTOR inhibitors may play a role in a variety of other cancers. In fact, the FDA has approved everolimus for the treatment of some patients with renal (kidney) cell carcinoma and breast cancer. Recent groundbreaking research in mice also suggests that these inhibitors may be able to slow aging, and further studies.
Feb 17, 2014 · To achieve this, it will be necessary to identify biomarkers of mTOR pathway activation and evaluate the sensitivity of the mTOR activated breast cancer population to mTOR inhibition. 4EBP1 is phosphorylated by mTOR into p4EBP1, which is a downstream effector of the mTOR pathway (Figure 3).Cited by: 28. These data suggest a strong possibility of interaction and relevance of PIM kinases and the PI3K/AKT/mTOR network in the regulation of ovarian cancer. In Breast Cancer. In many kinds of breast cancer, aberrations in the PI3K/AKT/mTOR pathway are the most common genomic abnormalities.